CareToLive RSS
Subscribe to the CareToLive RSS feed for up to date news and developments surrounding the legal battle against the FDA and more. (RSS feed reader required)
Subscribe to the CareToLive RSS feed for up to date news and developments surrounding the legal battle against the FDA and more. (RSS feed reader required)
Spread The Word
Please help spread the word about CareToLive. Any of the information found on this website can be distributed and shared freely. We only ask that you provide a link back to this website if you publish our content.
Please help spread the word about CareToLive. Any of the information found on this website can be distributed and shared freely. We only ask that you provide a link back to this website if you publish our content.
Donations
CareToLive is a not for profit corporation; however, donations are NOT tax exempt.
CareToLive is a not for profit corporation; however, donations are NOT tax exempt.
Posts Tagged ‘CareToLive’
Provenge is approved!
- Provenge has been approved! Thank you to all who helped achieve this important milestone for cancer patients.
LATEST POSTS
- 11/27/2011 - Care To Live Board Member Ted Girgus Dies of Prostate Cancer
- 09/06/2011 - Care To Live Update on SEC OIG Investigation into April 28, 2009 Dendreon Bear Raid
- 07/13/2011 - 3 Minute Video Explaining Provenge Treatment
- 06/20/2011 - Abigail Alliance Plans FDA PROTEST June 28
- 06/09/2011 - RIP Charles A. Reinwald — Cancer Cure Coalition Founder
- 04/29/2011 - Care To Live Submits Moment of Silence to CMS
- 04/28/2011 - HHS Desperately Needs Transparency Lessons From CMS
- 04/23/2011 - Please Post for Provenge!
- 04/19/2011 - Another Interim Provenge Prostate Cancer Immunotherapy CMS FOIA Response
- 04/16/2011 - PROVENGE! PROVENGE! GET YOUR PROVENGE HERE!
MOST POPULAR
- Setting the Record Straight
- Provenge Is Approved But The Lies Continue
- Provenge Works & Costs the Same as Chemo & Comments by Bishop
- The Bloodshed, Bogus Threats, Birth Defects, Bashers Cover Letter
- PROVENGE WILL BE COVERED BY MEDICARE
- CareToLive sends a Freedom of Information Request to the Centers for Medicare & Medicaid Services
- ASCO Tells CMS It Should Cover Provenge
- The Centers for Medicare and Medicaid Services are requesting comments.
- Dr. Snuffy Myers Advocates For Provenge Treatment
- Senators Specter and Kerry - CMS Has Some 'Splaining To Do
WHATS GOING ON
This Is An Emergency!
We rallied outside the FDA building in Rockville, Maryland on September 18th. Now there are buses riding around Rockville and Washington, D.C., further protesting the shenanigans that took place inside the FDA building, as well as outside.
The FDA has gotten caught up with Wall Street. While it is supposed to be busy with evaluating food and drugs, its employees just can't keep their eyes off the money. So that is how decisions are being made these days.
This Is An Emergency!
We rallied outside the FDA building in Rockville, Maryland on September 18th. Now there are buses riding around Rockville and Washington, D.C., further protesting the shenanigans that took place inside the FDA building, as well as outside.
The FDA has gotten caught up with Wall Street. While it is supposed to be busy with evaluating food and drugs, its employees just can't keep their eyes off the money. So that is how decisions are being made these days.
WE'LL BE BACK
These people traveled from all across the country to protest outside the FDA Building in Rockville, Maryland. The FDA has stopped a safe and effective treatment from getting to men who need it now. The treatment is called Provenge and it treats men who have late stage prostate cancer.
The FDA appointed a panel of experts to help it decide on the safety and efficacy of Provenge. That panel voted 17-0 that Provenge was safe. And it voted 13-4 that Provenge showed substantial evidence it worked. And yet the FDA delayed it. Now it could be a year, a year and a half or it could be three years. It could be forever.
These people will keeping coming back to Rockville and they hope others will join them until the courts, the FDA, Congress or somebody does something about this travesty.
These people traveled from all across the country to protest outside the FDA Building in Rockville, Maryland. The FDA has stopped a safe and effective treatment from getting to men who need it now. The treatment is called Provenge and it treats men who have late stage prostate cancer.
The FDA appointed a panel of experts to help it decide on the safety and efficacy of Provenge. That panel voted 17-0 that Provenge was safe. And it voted 13-4 that Provenge showed substantial evidence it worked. And yet the FDA delayed it. Now it could be a year, a year and a half or it could be three years. It could be forever.
These people will keeping coming back to Rockville and they hope others will join them until the courts, the FDA, Congress or somebody does something about this travesty.

RIP Charles A. Reinwald — Cancer Cure Coalition Founder
June 9th, 2011 | Posted by CTLWith our deepest condolences we mourn the loss from prostate cancer, June 2, 2011 at 85 years of age, of one of Care To Live’s fiercest warriors during our battle for Provenge’s approval. We never did, nor could we, thank him enough for all his help. Sometimes with death there is a revisiting of the person, and we welcome this opportunity to bring you Charles A. Reinwald the man, and his unique and incredible cancer foundation, with its focus on healing cancer, both medically and holistically.
A link to his website has always been right up there, on the top of our home page. Please add it to your ‘to do’ list. If you are a cancer patient, the Cancer Cure Coalition should be your first line of defense.
http://www.cancercurecoalition.org
Cancer Cure Coalition Mission Statement
http://www.cancercurecoalition.org/mission.html
Charles A Reinwald Biography
http://www.cancercurecoalition.org/board.html
Charles became a member of Care To Live early on. He was a great advocate of strengthening the immune system through diet and lifestyle changes, as well as medicine. Throughout the years Charles offered us advice, and support. He was fighting many wars, on many cancer fronts, but was never too tired to write one more letter or one more article, or to offer words of encouragement in our darkest hours, when we needed them most.
Charles was a rarity today. A true patient advocate, not beholden to any corporate or financial conflicts of interests. He was not an investor in Dendreon which frustrated the likes of those reporters whose deviant agendas were to erroneously portray Provenge as ineffectual, such as Matthew Herper of Forbes Magazine.
A brilliant man, he strove to understand health and wellness better, utiliizing his vast talents to educate and share what he learned with others. That is what made him truly stand out from the pack.
Care to Live literally stood shoulder to shoulder with Charles at our Rockville, Maryland FDA protest on September 18, 2007. He was one of our keynote speakers.
Charles A. Reinwald lives on in the families who will receive Provenge, those patient advocate and those with cancer whose lives he touched directly, his wife, his children, several of whom attended our Provenge 10 city rally in Cleveland in 2008, his grandchildren, and through his wonderful Cancer Cure Coalition Foundation.
I strongly urge people to send donations to:
The Cancer Cure Coalition
305 Beach Road, Suite 204
Tequesta, FL 33469
Telephone: (561) 747-2127
a 501 (C) (3) tax exempt charitable organization. Your donations are tax deductible pursuant to the Internal Revenue Code.
* * * * *
In February 2008 Mr. Reinwald took the FDA to task in this press release.
http://www.reuters.com/article/2008/02/21/idUS136546+21-Feb-2008+PRN20080221
Cancer Cure Coalition Proposes Major Changes at the FDA
Thu Feb 21, 2008 7:45am EST
Tags: Cancer Cure Coalition, Care To Live, CareToLive, Charles A. Reinwald, Charles Reinwald, Dendreon, dr richard pazdur, Dr. Howard I. Scher, FDA, Howard Scher, novacea, Proquest Investments, Prostate Cancer, provenge
Posted in The Cause | 1 Comment »
Care To Live Submits Moment of Silence to CMS
April 29th, 2011 | Posted by CTLDear CMS,
Please consider first and foremost the men and the families who love them. These are the true beneficiaries of the Provenge Medicare coverage. To you they may be portrayed as points on a graph, but to us, each and every one of these men, matter greatly. We call them Dad, Grandpa, Son, Brother and Husband.
During the approval and now coverage process, we have experienced moments of extreme joy and devastating heartbreak. The almost five year old continuing Provenge saga, ongoing since Dendreon first filed the clinical portion of their Biologics License Application with the FDA in 2006, has ended up on your doorstep to make a coverage determination by June 30. So many of our men’s hopes and health are now riding on you.
We at Care To Live would like to make clear to CMS, FDA, NCI and all the other government agencies peripherally involved, that this process that Provenge and other treatments go through is much too long and much too arduous for the patients awaiting treatment. Serious consideration must be given to find ways to get these exciting new treatments to the patients who are without viable alternatives to death, sooner, including passage of the Abigail Alliance sponsored Access Act.
The FDA in particular, needs to help bring treatments for late stage disease, like late stage prostate cancer, to the patients earlier. During the Provenge approval process, the FDA and the NCI sadly acted as patient adversaries and barriers, instead of the bridge that we were promised.
Within CMS’ own walls, mistakes were made. We hope you will strive to avoid these careless actions in the future. Never should safety and efficacy, already put through a long and laborious FDA review process, ever be evaluated by your agency. If you decide to evaluate a treatment based upon your stated intentions, such as uniformity of coverage and classification of reimbursement, then you must make it very clear at the outset that this is your intention.
CMS lacks authority to re-evaluate data provided by the FDA for a treatment’s safety and efficacy. Such action is particularly ill conceived when it is a treatment for late stage cancer. Without fast action by Dendreon, patient advocates, and several Congressmen, many more men may have been denied treatment. Total catastrophe was averted but not before your agency came close to creating chaos as seen through the eyes of many patients, some of whom urged Congress to get involved.
This should never be allowed to happen again.
Despite what some have said in these comments and elsewhere, making late stage prostate cancer patients out to be sick old men, that is just plain wrong. Most are still active, vital people, with no outward signs of disease. Some are still quite young, and all, if left untreated, will die too early of a very painful disease.
We are not about to let that happen. Care To Live Continue Reading Care To Live Submits Moment of Silence to CMS »
Popularity: 28%
Tags: , abigail alliance, Arnold Mass, Bruce Holmes, Bruce Tower, Care To Live, CareToLive, Center for Medicare and Medicaid, CMS, CTL, Dendreon, Greg Luter, HHS, Howard Cassell, Immunotherapy, John Fish, Kerry Donahue, Louis B. Jacques, Melody Davis Bennett, Mike Kearney, Prostate Cancer, provenge, Ray Matyshin, Richard Ripp, Rory Kearney, Stephen Study, Ted Girgus
Posted in The Cause | 1 Comment »
HHS Desperately Needs Transparency Lessons From CMS
April 28th, 2011 | Posted by CTLHuman Health and Resources (HHS) transparency rules differs greatly between divisions. Center for Medicaid and Medicare (CMS) has been forthcoming with our Freedom of Information (FOIA) requests, while the Food and Drug Administration (FDA) and the National Cancer Institute (NCI) continue stalling.
Read more at Pharmalot http://www.pharmalot.com/2011/04/the-fda-conflicts-of-interest-provenge-e-mails/
Popularity: 23%
Tags: Alison Martin, Care To Live, CareToLive, CMS, FDA, HHS, howard i scher, Katherine Sebilius, Louis B. Jacques, maha hussain, National Cancer Institute, NCI, Richard Pazdur
Posted in The Cause, The Dysfunctional FDA | Post a Comment »
Please Post for Provenge!
April 23rd, 2011 | Posted by CTLClick Here >> to go to the CMS Comment Page
The April 29, 2011 Deadline is fast approaching. Take Nothing for granted.
Please take a moment to write a sentence or two to the Centers for Medicaid and Medicare (CMS) requesting them to continue providing coverage for Provenge, the FDA approved immunotherapy for late stage prostate cancer. It is a non toxic, non invasive FDA approved treatment, safer and more effective than anything that has been previously approved.
1 in 6 men get prostate cancer in their lifetimes. 30,000 a year go on to die from it. Provenge is the first approved treatment of its kind, which utilizes your own immune system to fight off the cancer.
In order to post, you must first open the CMS PHI Posting Policy link and then remember to click the box below it:
Thank you for your prompt attention to this matter as this is time sensitive.
PS: If you have friends that will help, please email and forward. TIA
http://caretolive.com/Click Here >> on the CMS Comment Page to comment on the Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer (00422N).
Care To Live urges all of its friends and members to post a comment on the Centers for Medicare & Medicaid Services (CMS) web page encouraging them to support coverage of Dendreon’s Provenge.
Thank You,
Rory Kearney
President
Care To LIve,
a not for profit corporation
View Public Comments CAG-00422N Comment Period: 03/30/2011-04/29/2011
http://www.cms.gov/medicare-coverage-database/details/nca-view-public-comments.aspx
?NCAId=247&ExpandComments=n&ver=11&NcaName=Autologous+Cellular+Immunotherapy+Treatment+of+
Metastatic+Prostate+Cancer&DocID=CAG-00422N&SearchType=
Advanced&bc=IAAAABAAEAAA&
Date
Pos.
Neg.
Total
31-Mar
0
2
2
1-Apr
53
1
54
2-Apr
12
0
12
3-Apr
15
0
15
4-Apr
54
0
54
5-Apr
14
0
14
6-Apr
11
0
11
7-Apr
3
0
3
8-Apr
2
0
2
9-Apr
2
0
2
10-Apr
1
0
1
11-Apr
3
0
3
12-Apr
0
0
0
13-Apr
2
0
2
14-Apr
0
0
0
15-Apr
28
0
28
16-Apr
14
1
15
17-Apr
9
0
9
18-Apr
26
0
26
19-Apr
106
1
107
20-Apr
28
1
29
383
6
389
Popularity: 21%
Tags: Care To Live, CareToLive, Centers for Medicaid and Medicare, cms caretolive, Dendreon, Immunotherapy, Prostate Cancer, provenge
Posted in The Cause | 1 Comment »
Care To Live Expects Final CMS FOIA Documents by April 15
March 26th, 2011 | Posted by CTLCare To Live has been notified by the Department of Justice (DOJ) that the final FOIA response from CMS is expected to be completed and released to CTL not later than April 15, 2011.
As soon as it is released, it will be posted here in its entirety.
Popularity: 14%
Tags: CareToLive, cms fda ctl Care To Live, Dendreon, Immunotherapy, Prostate Cancer, provenge
Posted in The Cause, The Dysfunctional FDA, The Lawsuit | Post a Comment »
Dendreon’s NJ Plant Expansion Approved by FDA — FINALLY!
March 10th, 2011 | Posted by CTLGreat news from Dendreon today!
The FDA finally approved the remaining 75% of treatment stations at their New Jersey plant that manufactures Provenge.
This will quadruple their manufacturing capability and greatly help to alleviate some of the current supply/demand problem.
Two more plants in Los Angeles and Atlanta are also expected to be able to begin production in the near future.
Care To Live along with thousands of Patients, Urologists and Oncologists are thrilled that doctors will now be able to treat thousands more men with Provenge, however we will not sleep well until all the men who need Provenge can get it.
Popularity: 13%
Tags: Care To Live, CareToLive, Dendreon, FDA, Prostate Cancer, provenge
Posted in The Cause, The Dysfunctional FDA | 3 Comments »
Care To Live Receives FOIA Documents From CMS
February 21st, 2011 | Posted by CTLToday CTL received an interim response to its two previous FOIA request made to CMS. The documents were retrieved upon a search performed by Dr Louis Jacques. We received 258 pages of which 74 pages were redacted under claimed exemptions of FOIA (5 U.S.C. 552 (b)(2), (b)(5) and (b)(6)).
Although the pdf’s are not in 100% chronological order it is probably easiest to comprehend each of the 5 individual pdfs, from back to front.
1-cms-foia-0221.pdf
2-cms-foia-02211.pdf
3-cms-foia-02-21.pdf
4-cms-foia–02-21.pdf
5-cms-foia-0221.pdf
Popularity: 15%
Tags: Care To Live, CareToLive, CMS, Dendreon, foia, Louis B. Jacques, Prostate Cancer, provenge
Posted in The Cause, The Lawsuit | 1 Comment »
Race To Undo The Cure
February 21st, 2011 | Posted by Mike KearneyMatthew Herper, a writer for Forbes magazine and Forbes.com, has a biased, one-directional view of Dendreon’s Provenge, the first and only FDA-approved immunotherapeutic treatment for men with late stage prostate cancer. He continues to trip over his own feet in his attempts to lower the boom on Dendreon and Provenge. Over the past several years he even has attacked Care To Live, a prostate cancer patient advocacy group.
Mr. Herper could care less about the 30,000 men dying each year from an excruciatingly painful disease. He could care less about hurting a company financially that is attempting to cure not just prostate cancer, but many other forms of cancers as well. And he could care less about uncovering the malfeasance at the FDA Continue Reading Race To Undo The Cure »
Popularity: 13%
Tags: Care To Live, CareToLive, Dendreon, Forbes, Immnotherapy, Matt Herper, Matthew Herper, Prostate Cancer, provenge, Richard Pazdur
Posted in The Cause | 12 Comments »
Care To Live Attorney Kerry M. Donahue Argues for Pazdur’s Deleted Documents
December 9th, 2010 | Posted by Kerry DonahueI prepared for orals expecting a lot of questions. There were not many questions asked by Judge Norris or Judge Martin but quite a few by Judge Cook. Judge Norris and Martin are a couple of salty old dogs and seem a bit more lighthearted then many of their stiffer brethren.
I had 15 minutes, 5 of which I saved for rebuttal. I presented the issue and spoke about how this case was different then most FOIA cases in that we know that there were, and maybe still are, requested documents on the computer of a single individual at the FDA.
We know this by virtue of Richard Pazdur’s admittance that he had the documents on his computer but he deleted them. So in this case the CDER division of the FDA knows where to look. Continue Reading Care To Live Attorney Kerry M. Donahue Argues for Pazdur’s Deleted Documents »
Popularity: 15%
Tags: Care To Live, CareToLive, CDER, Dendreon, DOJ, FDA, Immunotherapy, Kerry M. Donahue, Prostate Cancer, provenge, Richard Pazdur
Posted in The Cause, The Dysfunctional FDA | 1 Comment »
Care To Live Again Requests CMS FOIA Reply
December 3rd, 2010 | Posted by CTLCare To Live Counsel Kerry M. Donahue sent a letter to the Centers for Medicaid and Medicare Services (CMS), as a final gesture to resolve the Freedom Of Information (FOIA) conflicts with their agency. However, if the the status quo remains, and we receive no response, Kerry has already started preparing litigation against them and will file on December 10, 2010, if they choose to go down that road.
(Click picture to enlarge. Download pdf here kerrydonahuecmsletter.pdf)
Popularity: 13%
Tags: Care To Live, CareToLive, Centers for Medicaid and Medicare Services, CMS, Dendreon, foia, Freedom of Information Act, Immunotherapy, Kerry M. Donahue, Prostate Cancer, provenge
Posted in The Cause, The Lawsuit | Post a Comment »